Document Resume Ed 300 932 Ec 211 076 Title Aids
Total Page:16
File Type:pdf, Size:1020Kb
DOCUMENT RESUME ED 300 932 EC 211 076 TITLE AIDS Issues (Part 1). Hearings before the Subcommittee on Health and the Environment of the Committee on Energy and Commerce. House of Representatives, One Hundredth Congress, First Session (March 10 1987--Cost and Availability of AZT; April 27, 1987--AIDS and Minorities; September 22, 1987--AIDS Research and Education). INSTITUTION Congress of the U.S., Washington, DC. House Committee on Energy and Commerce. PUB DATE Sep 87 NOTE 280p.; Serial No. 100-68. Portions contain small/marginally legible print. AVAILABLE FROM Superintendent of Documents, Congressional Sales Office, U.S. Government Printing Office, Washington, DC 20402. PUB TYPE Legal/Legislative/Regulatory Materials (090) -- Viewpoints (120) -- Reports - Descriptive (141) EDRS PRICE MFO1 /PC12 Plus Postage. DESCRIPTORS *Acquired Immune Deficiency Syndrome; *Diseases; *Drug Therapy; Outcomes of Treatment; *Public Health; *Special Health Problems IDENTIFIERS AZT (Drug) ABSTRACT The texts of three nearings on issues connected with AIDS (Acquired Immune Deficiency Syndrome) are recorded in this document. The first hearing concerne,' the availability and cost of the drug azidothymidine (AZT) for v,c.ims of the disease and considered such questions as what a fair price for AZT is, who will pay for people currently being treated free, who will pay for people after the drug is approved, who is responsible for people who cannot pay. The second hearing (which was held in Houston, Texas) was designed to bring public attention to the disproportionate dangers that AIDS poses for minorities in America--an issue that has been largely unaddressed. The purpose of the third hearing was to build on the already established public acceptance of the need for AIDS education and research by securing adequate and speedy government support for this work. Testimony is included from representatives of such organizations as the Jefferson Davis Hospital in Texas, the General Accounting Office, the People with AIDS Coalition, the American Foundation for AIDS Research, the Cen*.irs for Disease Control, the Gay Mens' Health Crisis, the Steering Committee on Aids of the National Academy of Sciences, and the Department of Health and Human Services. (DB) Reproductions supplied by EDRS are the best that can be made from the original document. AIDS ISSUES (Part 1) HEARINGS BEFORE THE SUBCOMMITTEE ON HEALTH AND THE ENVIRONMENT OF THE COMMITTEE ON ENERGY AND COMMERCE HOUSE OF REPRESENTATIVES ONE HUNDREDTH CONGRESS FIRST SESSION MARCH 10, 1987COST AND AVAILABILITY OF AZT APRIL 27, 1987AIDS AND MINORITIES SEPTEMBER 22, 1987AIDS RESEARCH AND EDUCATION Serial No. 100-68 r'rinted for the "se of the Committee on Energy and Commerce U S DEPARTMENT OF EDUCA' iON Office of Educational Research and Improve rent EDUCATIONAL RESOURCES INFORMATION CENTER (ERIC/ EXhisdocument has been reproduced as received from the person or organication originatin it C' Minor changes have oeen made to improve reproduction quality Points of view or oprions stated in this docu. ment do not necessarily represent official 0E111 position or policy U.S. GOVERNMENT PRINTING OFFICE 72635,-. WASHINGTON :1987 ForWe by the Superintendent of Documents, Congressional Sales Office U S Government Printing Office, Washington, DC 20402 2 BEST COPY AVAILABLE I COMMITTEE ON ENERGY AND COMMERCE JOHN D DINGELL, Michigan, Chairman JAMES H SCHEUER, New York NORMAN F LENT, New York HENRY A WAXMAN, California EDWARD R MADIGAN, Illinois PHILIP R. SHARP, Indiana CARLOSJMOORHEAD, California JAMES J FLORIO, New Jersey MATTHEW J. RINALDO, New Jersey EDWARD J. MARKEY, Massachusetts WILLIAM E DANNEMEYER, California THOMAS A LUKEN, Ohio ,_.0B WHITTAKER, Kansas DOUG WALGREN, Pennsylvania THOMAS J TAUKE, Iowa AL SWIFT, Washington DON RITTER, Pennsylvania MICKEY LELAND, Texas DAN COATS, Indiana CARDISS COLLINS, Illinois THOMAS J BLILEY,JR ,Virginia MIKE SYNAR, Oklahoma JACK FIELDS, Texas WJ "BILLY" TAUZIN, Louisiana MICHAEL G. OXLEY, Ohio RON WYDEN, Oregon HOWARD C NELSON, Utah RALPH M HALL, Texas MICHAEL BILIRAKIS, Ronda DENNIS E ECKART, Ohio DAN SCHAEFER, Colorado WAYNE DOWDY, Mississippi JOE BARTON, Texas BILL RICHARDSON, New Mexico SONNY CALLAHAN, Alabama JIM SLATTERY, Kansas GERRY SIKORSKI, Minnesota JOHN BRYANT, Texas JIM BATES, California RICK BOUCHER, Virginia JIM COOPER, Tennessee TERRY L BRUCE, Illinois WM MICHAEL KITZMILLER,Staff Director PAULCSMITH,Minority Chief CounO/Staff Director SUBCOMMITTEE ON HEALTH AND THE ENVIRONMENT HENRY AWAXMAN. California, Chairman JAMES H SCHEUER, New York EDWARD R MADIGAN, Illinois DOUG WALGREN, Pennsylvania WILLIAM E DANNEMEYER, California RON WYDEN, Oregon BOB WHITTAKER, Kansas GERRY SIKORSKI, Minnesota THOMAS J TAUKE, Iowa JIM BATES, California DAN COATS, Indiana TERRY L BRUCE, Illinois THOMAS J BLILEY. JR , Virginia MICKEY LELAND, Texas JACK FIELDS, Texas CARDISS COLLINS, Illinois NORMAN F LENT, New York RALPH M HALL Texas (Ex Officio) WAYNE DOWDY. Mississippi JOHN L DINGET-L, Michigan (Ex Officio) KAREN NELSON,Staff Director TIMOTHY M WESTMORELAND, Counsel ANDREASGSCHNEIDER,Counsel EDWINHALLEN,Minority Counsel CONTENTS Page Hearings held on: March 10, 1987 . 1 April 27, 1987 (Houston, TX) 53 September 22, 1987 155 Testimony of: Awe, Robert J., chief, Pulmonary Medicine, Jefferson Davis Hospital...... 145 Barry, David, vice president, research, Burroughs Wellcome Co......... ... 4 Bascetta, Cynthia, Human Resources Division, General Accounting Office 176 Callen, Michael, Community Research Initiative, People With AIDS Coa- lition, Inc 273 Corey, Lawrence, director, AIDS Treatment Evaluation Program and prc- fessor of medicine, University of Washington 270 Haigler, T.E., Jr., president and chief executive officer, Burroughs Wel' come Co . 4 Haughton, James, director, city of Houston Department of Health and Human Services 78 Kihnel, Chris, president, People With AIDS Coalition 133 Krim, Mathilde, associate research scientist, St. Luke's-Roosevelt Hospi- tal Center and Columbia University, and founding chairwoman, Ameri- can Foundation for AIDS Research 77 Lane, J. Michael, Director, Center for Prevention Services, Centers for Disease Control, Public Health Service, Department of Health and Human Services 60 Lawson, Rev. William, Wheeler Avenue Bapt'st Church... ....... .... ...... 128 Lovell, Sue, board of directors, AIDS Foundation 132 McFarren, Ann E., executive director, AIDS Action Council, and presi- dent, AIDS Action Foundation 158 McKinnev, --narles, director of education, Gay Mens' Health Crisis.... 208 Manse'i, Peter, Institute for Immunological Disorders 143 Miike, Lawrence, Senioe Associate-Health Programs, Office of Technology Assessment ..... ......................... 181 Perez, Jose, Gay and Lesbian Hispanics Unidas 130 Roper, William L., Administrator, Health Care Financing Administra- tion, Department of Health and Human Services 33 Sweeney, Tim, deputy director for government relations, Gay Mens' Health Crisis. 208 Taylor, Elizabeth, national chairman, American Foundation for AIDS Research 167 Terry, Robert J., president, Texas Southern University. 58 Weissman, Irving L., professor of pathology, Stanford University, member of Steering Committee on AIDS, National Academy of Sciences.... 264 Windom, Robert E., Assistant Secretary for Health, Public Health Serv- ice, Department of Health and Human Services .......... ........ ..... 27 Zimmerman, Michael, Senior Associate Director, Human Resources Divi- sion, General Accounting Office 176 IV Page Material submitted for the record by AIDS Foundation Houston, statement . 152 American Pharmaceutical Association, statement 51 Bruce, Hon. Terry, statement ............................................ 3 Health and the Environment Subcommittee, materials supplied by Amer- ican Social Health Association AIDS Hotline outlining their various programs 214 Office of Technology Assessment, statement "How Accurate is AIDS Anti- body Testing?" was submitted in response to questions of Mr Danne- meyer at the hearing 189 5 1 a AIDS ISSUES Cost awl Availability of AZT TUESDAY, MARCH 10, 1987 HOUSE OF REPRESENTATIVES, COMMITTEE ON ENERGY AND COMMERCE, SUBCOMMITTEE ON HEALTH AND THE ENVIRONMENT, Washington, DC. The subcommittee met, pursuant to notice at 9:55a.m., in room 2322, Rayburn House Office Building, Hor... HenryA. Waxman (chairman) presiding. Mr. WAXMAN. The meeting of the subcommitteewill come to order. Last September the Department of Health and HumanSe vices and the Burroughs Wellcome Company madea dramatic joint an- nouncement. There was an AIDS drug. The drug AZT had beenin clinical trials in humans for 7 months. The trialswere double- blinded and placebo-controlled. That is, bysecret random selection half of the patients received AZT and half receiveda placebo. A few months later researchers began toreport that some AIDS patients were clearly getting better. Otherswere dying. The re- searchers insisted that a scientific safety board breakthe secret code'. I see if the drug was producing these results. In September the safety board revealed thatabout 1 out of 8 pa- tients in the control group had died compared toone out of 145 of the patients receiving AZT. Given this information,both HHS and Burroughs Wellcome decided that it would be unethicalto continue the study, that keepingsome patients off the drug endangered their lives. While formal approval procedures began, all controlgroup pa- tients were given AZT. In addition, Burroughs Wellcomeand HHS began to supply AZT free of charge to any AIDS patientin Amer- ica